Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Stribild and effects on HIV reservoir and immune activation
2014-004015-36Phase 4Completed
- Sponsor
- ASST Santi Paolo e Carlo
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil in Human immunodeficiency virus infection type 1, sponsored by ASST Santi Paolo e Carlo. Primary endpoints: Change in total HIV DNA after switch to Stribild, Change in integrated HIV DNA after switch to Stribild and 1 more. Started Oct 2014; status: completed.
02
Drugs
emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2014-004015-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004015-36.